View Future GrowthPredilife 過去の業績過去 基準チェック /06Predilifeの収益は年間平均-8.2%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間13.3% 40.7%割合で 増加しています。主要情報-8.25%収益成長率-6.96%EPS成長率Biotechs 業界の成長-14.59%収益成長率40.74%株主資本利益率n/aネット・マージン-470.74%前回の決算情報31 Dec 2025最近の業績更新Reported Earnings • Jul 02Full year 2025 earnings released: €1.00 loss per share (vs €1.13 loss in FY 2024)Full year 2025 results: €1.00 loss per share (improved from €1.13 loss in FY 2024). Revenue: €854.5k (up 73% from FY 2024). Net loss: €3.93m (loss narrowed 7.7% from FY 2024).すべての更新を表示Recent updatesNew Risk • Jul 02New major risk - Revenue and earnings growthEarnings have declined by 8.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.6m free cash flow). Negative equity (-€16m). Earnings have declined by 8.2% per year over the past 5 years. Revenue is less than US$1m (€854k revenue, or US$977k). Minor Risk Market cap is less than US$100m (€8.88m market cap, or US$10.1m).Reported Earnings • Jul 02Full year 2025 earnings released: €1.00 loss per share (vs €1.13 loss in FY 2024)Full year 2025 results: €1.00 loss per share (improved from €1.13 loss in FY 2024). Revenue: €854.5k (up 73% from FY 2024). Net loss: €3.93m (loss narrowed 7.7% from FY 2024).New Risk • Jun 30New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.69m (US$9.92m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€15m). Revenue is less than US$1m (€728k revenue, or US$831k). Market cap is less than US$10m (€8.69m market cap, or US$9.92m). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (8.2% average weekly change).New Risk • Jun 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€15m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€728k revenue, or US$827k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (8.2% average weekly change). Market cap is less than US$100m (€9.07m market cap, or US$10.3m).お知らせ • May 27Predilife S.A., Annual General Meeting, Jun 30, 2026Predilife S.A., Annual General Meeting, Jun 30, 2026. Location: 1 rue royale bureaux de la colline, saint cloud FranceBoard Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Ombline de Villele was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • May 20Predilife S.A., Annual General Meeting, Jun 23, 2025Predilife S.A., Annual General Meeting, Jun 23, 2025. Location: 1 rue royale bureaux de la colline, batiment b 9e etage, saint cloud France収支内訳Predilife の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:0GA 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費31 Dec 251-43030 Sep 251-43030 Jun 251-43031 Mar 251-43031 Dec 240-43030 Sep 240-42030 Jun 240-52031 Mar 240-42031 Dec 230-42030 Sep 230-42030 Jun 230-42031 Mar 230-42031 Dec 220-42030 Sep 220-32030 Jun 220-32031 Mar 220-32031 Dec 210-32030 Sep 210-32030 Jun 210-32031 Mar 210-32031 Dec 200-22030 Sep 200-21030 Jun 200-21031 Mar 200-21031 Dec 190-21030 Sep 190-31030 Jun 190-31031 Mar 190-31031 Dec 180-21030 Sep 180-21030 Jun 180-11031 Mar 180-11031 Dec 170-210質の高い収益: 0GAは現在利益が出ていません。利益率の向上: 0GAは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: 0GAは利益が出ておらず、過去 5 年間で損失は年間8.2%の割合で増加しています。成長の加速: 0GAの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: 0GAは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 1.2% ) と比較することは困難です。株主資本利益率高いROE: 0GAの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/12 21:20終値2026/07/10 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Predilife S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Jean-Pierre LozaIn Extenso Financement & Marché
Reported Earnings • Jul 02Full year 2025 earnings released: €1.00 loss per share (vs €1.13 loss in FY 2024)Full year 2025 results: €1.00 loss per share (improved from €1.13 loss in FY 2024). Revenue: €854.5k (up 73% from FY 2024). Net loss: €3.93m (loss narrowed 7.7% from FY 2024).
New Risk • Jul 02New major risk - Revenue and earnings growthEarnings have declined by 8.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€2.6m free cash flow). Negative equity (-€16m). Earnings have declined by 8.2% per year over the past 5 years. Revenue is less than US$1m (€854k revenue, or US$977k). Minor Risk Market cap is less than US$100m (€8.88m market cap, or US$10.1m).
Reported Earnings • Jul 02Full year 2025 earnings released: €1.00 loss per share (vs €1.13 loss in FY 2024)Full year 2025 results: €1.00 loss per share (improved from €1.13 loss in FY 2024). Revenue: €854.5k (up 73% from FY 2024). Net loss: €3.93m (loss narrowed 7.7% from FY 2024).
New Risk • Jun 30New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.69m (US$9.92m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€15m). Revenue is less than US$1m (€728k revenue, or US$831k). Market cap is less than US$10m (€8.69m market cap, or US$9.92m). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (8.2% average weekly change).
New Risk • Jun 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-€15m). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m (€728k revenue, or US$827k). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (8.2% average weekly change). Market cap is less than US$100m (€9.07m market cap, or US$10.3m).
お知らせ • May 27Predilife S.A., Annual General Meeting, Jun 30, 2026Predilife S.A., Annual General Meeting, Jun 30, 2026. Location: 1 rue royale bureaux de la colline, saint cloud France
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 2 highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Ombline de Villele was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • May 20Predilife S.A., Annual General Meeting, Jun 23, 2025Predilife S.A., Annual General Meeting, Jun 23, 2025. Location: 1 rue royale bureaux de la colline, batiment b 9e etage, saint cloud France